tetano
Editor, Senior Moderator
NPJ Vaccines
. 2022 May 13;7(1):52.
doi: 10.1038/s41541-022-00475-z.
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
Nawamin Pinpathomrat[SUP] 1 [/SUP], Porntip Intapiboon[SUP] 2 [/SUP], Purilap Seepathomnarong[SUP] 1 [/SUP], Jomkwan Ongarj[SUP] 1 [/SUP], Ratchanon Sophonmanee[SUP] 1 [/SUP], Jariya Hengprakop[SUP] 1 [/SUP], Smonrapat Surasombatpattana[SUP] 3 [/SUP], Supattra Uppanisakorn[SUP] 4 [/SUP], Surakameth Mahasirimongkol[SUP] 5 [/SUP], Waritta Sawaengdee[SUP] 5 [/SUP], Supaporn Phumiamorn[SUP] 6 [/SUP], Sompong Sapsutthipas[SUP] 6 [/SUP], Chanon Kongkamol[SUP] 7 [/SUP], Thammasin Ingviya[SUP] 7 [/SUP], Pasuree Sangsupawanich[SUP] 4 [/SUP], Sarunyou Chusri[SUP] 8 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) have been shown to be insufficient to protect against variants of concern (VOCs), while viral vector vaccines remain protective against the infection. Herein, we conducted a preliminary study to evaluate the safety and immunity in an adult population who received the conventional 2 dosage-regimen of inactivated SARS-CoV-2 vaccine; with an additional intradermal ChAdOx1 nCoV-19 reciprocal dosage (1:5). An Intramuscular ChAdOx1 nCoV-19 booster was also included as a control. Immediate and delayed local reactions were frequently observed in the fractional intradermal boost, but systemic side effects were significantly decreased compared to the conventional intramuscular boost. The anti-RBD-IgG levels, the neutralising function against delta variants, and T cell responses were significantly increased after boosting via both routes. Interestingly, the shorter interval elicited higher immunogenicity compared to the extended interval. Taken together, a reciprocal dosage of intradermal ChAdOx1 nCoV-19 booster reduces systemic adverse reactions and enhances non inferiority humoral and cellular immune responses compared to a full dose of intramuscular boosting. These findings provide for an effective vaccine management during the shortages of vaccine supply.
. 2022 May 13;7(1):52.
doi: 10.1038/s41541-022-00475-z.
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
Nawamin Pinpathomrat[SUP] 1 [/SUP], Porntip Intapiboon[SUP] 2 [/SUP], Purilap Seepathomnarong[SUP] 1 [/SUP], Jomkwan Ongarj[SUP] 1 [/SUP], Ratchanon Sophonmanee[SUP] 1 [/SUP], Jariya Hengprakop[SUP] 1 [/SUP], Smonrapat Surasombatpattana[SUP] 3 [/SUP], Supattra Uppanisakorn[SUP] 4 [/SUP], Surakameth Mahasirimongkol[SUP] 5 [/SUP], Waritta Sawaengdee[SUP] 5 [/SUP], Supaporn Phumiamorn[SUP] 6 [/SUP], Sompong Sapsutthipas[SUP] 6 [/SUP], Chanon Kongkamol[SUP] 7 [/SUP], Thammasin Ingviya[SUP] 7 [/SUP], Pasuree Sangsupawanich[SUP] 4 [/SUP], Sarunyou Chusri[SUP] 8 [/SUP]
Affiliations
- PMID: 35562372
- PMCID: PMC9106663
- DOI: 10.1038/s41541-022-00475-z
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) have been shown to be insufficient to protect against variants of concern (VOCs), while viral vector vaccines remain protective against the infection. Herein, we conducted a preliminary study to evaluate the safety and immunity in an adult population who received the conventional 2 dosage-regimen of inactivated SARS-CoV-2 vaccine; with an additional intradermal ChAdOx1 nCoV-19 reciprocal dosage (1:5). An Intramuscular ChAdOx1 nCoV-19 booster was also included as a control. Immediate and delayed local reactions were frequently observed in the fractional intradermal boost, but systemic side effects were significantly decreased compared to the conventional intramuscular boost. The anti-RBD-IgG levels, the neutralising function against delta variants, and T cell responses were significantly increased after boosting via both routes. Interestingly, the shorter interval elicited higher immunogenicity compared to the extended interval. Taken together, a reciprocal dosage of intradermal ChAdOx1 nCoV-19 booster reduces systemic adverse reactions and enhances non inferiority humoral and cellular immune responses compared to a full dose of intramuscular boosting. These findings provide for an effective vaccine management during the shortages of vaccine supply.